Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • Acazicolcept (ALPN-101)
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
  • Careers
  • No menu assigned!

News Releases

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  management team  |  documents  |  committee composition  | 

  • September 7, 2021
    Summary ToggleAlpine Immune Sciences Announces Participation in September Investor Conferences
    SEATTLE --(BUSINESS WIRE)--Sep. 7, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the
    Read More
  • August 10, 2021
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results
    - Conference call and webcast today at 4:30 p.m. ET - SEATTLE --(BUSINESS WIRE)--Aug. 10, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a
    Read More
  • August 4, 2021
    Summary ToggleAlpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences
    SEATTLE --(BUSINESS WIRE)--Aug. 4, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial
    Read More
  • June 30, 2021
    Summary ToggleAlpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)
    - First Patient Dosed in NEON-2 Clinical Trial - SEATTLE --(BUSINESS WIRE)--Jun. 30, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today a
    Read More
  • June 24, 2021
    Summary ToggleAlpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration
    SEATTLE --(BUSINESS WIRE)--Jun. 24, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today that the first patient has been dosed in Synergy, a
    Read More
  • June 8, 2021
    Summary ToggleAlpine Immune Sciences Set to Join Russell 3000® Index
    SEATTLE --(BUSINESS WIRE)--Jun. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today Alpine is set to join the broad-market Russell 3000®
    Read More
  • June 4, 2021
    Summary ToggleAlpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting
    Alpine to hold an ALPN-202 Investor Event on Friday, June 4 at 7:00pm EDT SEATTLE --(BUSINESS WIRE)--Jun. 4, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases,
    Read More
  • June 2, 2021
    Summary ToggleAlpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting
    SEATTLE --(BUSINESS WIRE)--Jun. 2, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today made an oral presentation of preclinical data from the company’s
    Read More
  • June 2, 2021
    Summary ToggleAlpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer
    SEATTLE --(BUSINESS WIRE)--Jun. 2, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of industry veteran Zelanna Goldberg,
    Read More
  • May 19, 2021
    Summary ToggleAlpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting
    - Alpine to hold Investor Event on Friday, June 4 at 7:00pm ET - - Program abstracts are now live on the ASCO website - SEATTLE --(BUSINESS WIRE)--May 19, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments
    Read More

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • …
  • Next page Next
  • Last page Last
Displaying 21 - 30 of 136 results

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2022 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Management Team
    • Documents
    • Committee Composition